v3.25.4
Segment Information - Schedule of Segment Reporting Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]        
Total revenue from reportable segments $ 537,102 $ 481,069 $ 865,913 $ 773,332
Cost of commissions and other services revenue (103,034) (101,138) (172,135) (166,872)
Cost of goods sold—pharmacy revenue (205,194) (156,201) (397,973) (285,724)
Marketing expense (105,028) (97,725) (166,975) (161,489)
Technical development (9,595) (10,044) (19,506) (19,119)
Selling, general, and administrative (38,940) (45,021) (74,759) (81,166)
Adjusted Segment EBITDA 108,879 110,156 100,625 128,719
All Other Adjusted EBITDA 2,102 2,303 3,989 6,099
Corporate (26,250) (24,940) (51,962) (48,983)
Share-based compensation expense (3,475) (4,699) (7,802) (8,545)
Transaction costs (662) (6,719) (846) (7,544)
Depreciation and amortization (4,322) (5,060) (8,622) (10,659)
Loss on disposal of property, equipment, and software, net   (122)   (157)
Impairment of equity-method investment 1,000   1,000 0
Change in fair value of warrants 19,296 (7,642) 34,332 (7,642)
Interest expense, net (11,613) (23,721) (23,421) (46,752)
Loss before income tax benefit 82,955 39,556 45,293 4,536
Unallocated corporate expenses 17,400 17,300 35,200 32,800
Professional services 5,000 4,000 9,100 8,800
Facilities 1,400 1,300 2,700 2,800
Severance expenses 300   400 500
Financing transaction costs 300 6,700 500 7,000
Operating Segments        
Segment Reporting Information [Line Items]        
Total revenue from reportable segments 535,816 478,809 862,810 766,746
Cost of commissions and other services revenue
Cost of goods sold—pharmacy revenue
Marketing expense
Technical development
Selling, general, and administrative
Operating Segments | Senior        
Segment Reporting Information [Line Items]        
Total revenue from reportable segments 261,539 255,578 320,536 348,487
Cost of commissions and other services revenue (74,391) (75,042) (116,288) (116,169)
Cost of goods sold—pharmacy revenue 0 0 0 0
Marketing expense (84,056) (79,398) (121,686) (122,775)
Technical development 0 0 0 0
Selling, general, and administrative (640) (617) (1,147) (1,296)
Adjusted Segment EBITDA 102,452 100,521 81,415 108,247
Operating Segments | Healthcare Services        
Segment Reporting Information [Line Items]        
Total revenue from reportable segments 230,654 183,370 452,005 339,108
Cost of commissions and other services revenue (8,357) (7,932) (14,658) (13,812)
Cost of goods sold—pharmacy revenue (203,783) (155,009) (395,181) (283,375)
Marketing expense (2,235) (1,902) (4,623) (4,149)
Technical development (311) (592) (749) (1,200)
Selling, general, and administrative (15,122) (15,723) (28,736) (29,483)
Adjusted Segment EBITDA 846 2,212 8,058 7,089
Operating Segments | Life        
Segment Reporting Information [Line Items]        
Total revenue from reportable segments 43,623 39,861 90,269 79,151
Cost of commissions and other services revenue (17,404) (15,041) (35,382) (29,613)
Cost of goods sold—pharmacy revenue 0 0 0 0
Marketing expense (20,376) (17,172) (43,136) (35,667)
Technical development 0 0 0 0
Selling, general, and administrative (262) (225) (599) (488)
Adjusted Segment EBITDA $ 5,581 $ 7,423 $ 11,152 $ 13,383